Beckman Coulter launched the first AMH assay in 1999 and has set the standard for AMH testing, evidenced by more than 2,000 scientific articles and publications.

Source: Beckman Coulter

News • Infertility

Beckman Coulter launches Access AMH Advanced

Beckman Coulter announced the launch of an AMH test that uses a validated cut-off to aid in the assessment of poor ovarian response. This new assay helps clinicians predict poor ovarian response in those who plan to undergo controlled ovarian stimulation as part of an in vitro fertilisation (IVF) protocol. The AMH Advanced assay is available in European countries that accept the CE marking.

An ongoing challenge for clinicians is the lack of a gold standard to assess ovarian reserve and ovarian response. There is no universally accepted clinical cut-off to define a normal versus an abnormal result for any available measure of ovarian reserve. Validated AMH cut-offs for ovarian reserve and ovarian response provide clinicians with the information they need to develop a personalised protocol to individualise treatment for controlled ovarian stimulation and improve the benefits and risks for the patient.

“With the new Access AMH Advanced assay, clinicians now have a tool to predict poor ovarian response so they can establish individualised treatment for ovarian stimulation in women undergoing an assisted reproductive technology programme,” said Kathleen Orland, senior vice president & general manager of clinical chemistry immunoassay at Beckman Coulter Diagnostics.

Beckman Coulter AMH tests have played a fundamental role in studies that point to the importance of AMH testing in fertility. By assessing AMH levels with a simple blood test, clinicians can determine a woman's ovarian reserve and make informed treatment decisions for women struggling with infertility, undergoing IVF, or planning pregnancies later in life.

Source: Beckman Coulter

According to the World Health Organization (WHO), infertility affects millions of people of reproductive age worldwide, adversely impacting families and communities. Estimates suggest that 48 million couples and 186 million individuals live with infertility globally . AMH is a widely accepted biomarker used to evaluate several clinical conditions, including infertility treatment, menopause evaluation, ovarian dysfunction (such as polycystic ovary syndrome), gonadotoxic cancer treatment and ovarian surgery.

AMH testing has become increasingly important in monitoring female reproductive health to help provide personalised guidance, predict ovarian response to IVF treatment, and avoid ovarian hyperstimulation. The Advanced AMH assay provides accurate and validated assay-specific cut-offs to guide clinical use. The assay also aids in establishing the individual daily dose of the human recombinant follicle-stimulating hormone rFSH (follitropin delta) marked by Ferring Pharmaceuticals in controlled ovarian stimulation for the development of multiple follicles in women undergoing in vitro fertilisation.

“Beckman Coulter is the leading innovator in AMH testing, having pioneered the test over 20 years ago. Clinicians have continued to appreciate the utility of the test since, unlike other biomarkers, AMH has minimal variability throughout the menstrual cycle ,” said Heather Read-Harper, senior marketing manager for immunoassay and clinical chemistry at Beckman Coulter Diagnostics. “We continue on our innovator’s journey by delivering the only AMH assay on the market that provides its own validated cut-offs for ovarian response, while also assessing ovarian reserve.”

For more information on the AMH Advanced assay: https://www.beckmancoulter.com/products/immunoassay/access-amh

Source: Beckman Coulter

04.06.2021